Member Info for Marty130

Share PricesRenalytix Plc Share PriceRenalytix Plc Share Regulatory NewsResult of Fundraise

Renalytix Plc Regulatory News (RENX)

RENX Share

Price

RENX Share

News

1

RENX Share

Chat

198

RENX Share

Trades

511

RENX

Live RNS

3

Sponsored Content

Renalytix Plc Information

Add RENX to Timeline

Add RENX to Watchlist

Add RENX to Alert

Buy RENX Shares

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes

Get Live Data

Share Price:

10.00

Bid:

9.50

Ask:

10.50

Change:

-0.75 (-6.98%)

Spread: 1.00 (10.526%)Open: 10.00High: 10.00Low: 10.00Prev. Close: 10.75

Last checked at 18:42:22

Sponsored Content

Result of Fundraise

Today 17:30

RNS Number : 3207A

Renalytix PLC

22 September 2025

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION ("RESTRICTED JURISDICTION"). PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

22 September 2025

Renalytix plc

("Renalytix" or the "Company")

Result of Fundraise

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, confirms that, further to the Company's announcement released at 7:00 a.m. on 22 September 2025 (RNS Number: 2180A) (the "Fundraising Announcement"), the bookbuild has now closed and the Company has, conditionally, raised gross proceeds of £5.20 million by way of a successful placing of, and subscription for, a total of 54,741,582 new Ordinary Shares at the Issue Price of 9.5 pence per share (the "Placing and Subscription").

Oberon Capital (a trading name of Oberon Investments Limited) is acting as sole bookrunner in respect of the Placing. The Placing, which was significantly oversubscribed, was undertaken through an accelerated bookbuild process.

The Retail Offer remains open for individual investors until 4.30 p.m. on 25 September 2025 and the result of the Retail Offer will be made as soon as practicable thereafter.

James McCullough, CEO of Renalytix commented: "The successful res

Successful placing for renaltix, diluted share price for us!!!

The Retail Offer remains open for individual investors until 4.30 p.m. on 25 September 2025 and the result of the Retail Offer will be made as soon as practicable thereafter.

Yes, ask your broker.

Yes, my friend has more.

So true.

I'm sitting on nearly 3 million shares bought over the last week.. Today was a little painful.

Renaltix trading at 27c. No placing over there.

Just my thoughts, may lift little tomorrow, but for the longrun, don't see it making any furthermore until they hopefully announce stronger revenue..

Revenue data due this week.

From last year..

Renalytix PLC on Tuesday announced a successful fund raise alongside a narrowed annual loss.

The London-based diagnostics company said it had raised £11.8 million via a placing and subscription at 9 pence per share. In a statement on Monday, the firm said it hoped to raise at least £10 million.

Chief Executive James McCullough commented: ‘The strong demand we have seen for the fundraise supports our view that Renalytix offers investors unique access to a world-leading kidney prognostic test.’

He pointed out kidneyintelX.dkd is the only test to be approved by the US Food & Drugs Administration; granted full Medicare reimbursement at $950 per test; recommended in KDIGO clinical guidelines; available to approximately 14 million US diabetic kidney disease patients; and able to address the needs of approximately 260 million DKD patients globally.

‘We now have a strong cash and balance sheet position, we have taken positive actions to substantially reduce our monthly cash burn, and we are delivering quarter-on-quarter growth in orders, whilst also supporting a new customer launch. We believe these factors, combined, will take the company to profitability and cash flow break-even in approximately two years and that we have the potential to generate revenue of approximately $17.5 million in [financial 2027].’

Renalytix said net loss before tax narrowed to $33.5 million in the year ended June 30 from $45.6 million a year prior. Revenue slipped to $2.3 million from $3.4 million but general and administrative costs nosedived to $19.8 million from $28.7 million.

Shares in Renalytix rose 8.1% to 8.64 pence each in London on Tuesday.

GGG the share price will only shift upwards on better than expected revenue data. Presumably they are aware the data will indeed be positive to go ahead with this bold move.

GGG the Directors have taken part in a money for shares loan. They haven't simply taken a chance and bought more shares.

Yes BoD is lending money on share swap basis, not buying shares,.

Ok, but the placing is not happening until the 26th.

The cash the Directors are putting in is being converted into shares! Or did some miss that?

To pay for staff and fixed expenses.. Will soon be dissappear.

Could be weeks before we see a recovery, maybe the the long expected revenue update, if better than expected may help lift the stock.

Sales outpacing buys..

Could be..